Health
Astra Drug Doesn’t Help With Tough Form of Breast Cancer
This article is for subscribers only.
AstraZeneca Plc’s new medicine Truqap didn’t help patients with a hard-to-treat form of breast cancer live longer.
Scientists studied the drug in combination with a common chemotherapy in the late-stage study, the drugmaker said Tuesday. The volunteers had triple-negative breast cancer, one of the most challenging forms of the disease to treat, which had spread or couldn’t be operated.